Brain Research 1993-05-28

Increase of plasma adrenocorticotrophin and cortisol in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated dogs.

M Mizobuchi, T Hineno, Y Kakimoto, K Hiratani

Index: Brain Res. 612(1-2) , 319-21, (1993)

Full Text: HTML

Abstract

Neuroendocrine abnormality of the hypothalamic-pituitary-adrenal axis was investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated dogs as a model of Parkinson's disease. Blood samples were collected every 4 h for 3-4 days before MPTP treatment, around 2 and 4 weeks after the treatment of MPTP (2.5 mg/kg). Adrenocorticotrophin (ACTH) and cortisol concentrations in plasma were determined by radioimmunoassay. The concentrations of plasma ACTH and cortisol increased by 40% and 60% after MPTP treatment, respectively. Circadian rhythms of neither plasma ACTH nor cortisol concentrations were observed in both MPTP-treated and control dogs. This high hypothalamic-pituitary-adrenal function in MPTP-treated dogs suggests that MPTP may influence the activity of the hypothalamic neurons of the dog.

Related Compounds

  • 2'-METHYL MPT...

Related Articles:

The histochemical demonstration of MPTP oxidation in the postmortem human striatum.

1993-05-14

[Neurosci. Lett. 154(1-2) , 61-4, (1993)]

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) disrupts social memory/recognition processes in the male mouse.

1993-04-23

[Brain Res. 609(1-2) , 98-102, (1993)]

Imidazolium salt (DBZIM) reduces gliosis in mice treated with neurotoxicant 2'-CH(3) -MPTP.

2011-06-01

[CNS Neurosci. Ther. 17(3) , 148-57, (2011)]

2'-NH(2)-MPTP [1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine] depletes serotonin and norepinephrine in rats: a comparison with 2'-CH(3)-MPTP [1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine].

2002-11-01

[J. Pharmacol. Exp. Ther. 303(2) , 527-33, (2002)]

Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors.

1993-11-26

[Neurosci. Lett. 163(1) , 31-5, (1993)]

More Articles...